Pharmacology News

After a successful end-of-phase 2 meeting with the FDA, Biohaven Pharmaceuticals announced in a press release that intranasal vazegepant, a novel option for acute treatment of migraine, will soon be tested in a phase 3, double-blind, placebo-controlled trial.

Medicaid expansion may have led to reductions in opioid-related hospitalizations between 2005 and 2017, according to a study published in JAMA Internal Medicine.

Omalizumab may effectively treat food allergy symptoms in patients with alpha-gal syndrome, according to research from a small study that was to be presented at the American Academy of Asthma, Allergy & Immunology Annual Meeting.

A recent paper published in The Lancet Respiratory Medicine has led to a debate over whether or not people with COVID-19 should take ibuprofen and other NSAIDs.

A meta-analysis of randomized controlled trials published in the Annals of Internal Medicine showed that dual therapy was associated with lower risk for major bleeding in patients with nonvalvular atrial fibrillation after PCI compared with triple therapy.

A new point-of-care clinical decision tool, PEN-FAST, may help identify patients with reported penicillin allergies who can safely undergo oral challenges and receive beta-lactam antibiotics without needing formal allergy testing, according to research published in JAMA Internal Medicine.

High-risk pregnant women who were nonadherent to prescribed aspirin experienced greater risk for poor clinical outcomes compared with women who were adherent, according to research published in Hypertension.

People are using Craigslist to buy and sell lifesaving drugs, particularly insulin, according to a research letter published in JAMA Internal Medicine.

The FDA has issued a drug safety communication stating that it now requires a boxed warning for montelukast to strengthen the agency’s existing warning about the risk for neuropsychiatric events such as suicidal thoughts or actions associated with the drug, which is used to treat asthma and allergy, according to an agency press release.

Oral fluoroquinolones were prescribed appropriately only 15% of the time in long-term care facilities, according to results of a retrospective chart review published in the Journal of the American Geriatrics Society.